STOPCAP 1 Programme

What was this study about?

STOPCAP M1 is a worldwide collaborative effort that aims to quickly identify which treatments work best for men with metastatic, hormone-sensitive prostate cancer. This will be done through:

1. Systematic reviews of treatment effects

2. Identification of surrogate outcomes, by trying to find early measurements of prostate cancer control that predict later survival 

3. Establishing a repository of patient data, which will be used to tackle new questions about advanced prostate cancer and its treatment as they arise. 

For more information, please visit the STOPCAP 1 website.

What difference did this study make?

Please click below for more information about STOPCAP 1 results, so far:

• STOPCAP 1 (M0) – docetaxel, systematic review and aggregate data meta-analysis (Lancet, 2016)
• STOPCAP 1 (M0) – bisphosphonates, systematic review and aggregate data meta-analysis (Lancet 2016)
• STOPCAP 1 (M1) – docetaxel, systematic review and aggregate data meta-analysis
• STOPCAP 1 (M1) – bisphosphonates, systematic review and aggregate data meta-analysis
• STOPCAP 1 (M1) – abiraterone, systematic review and aggregate data meta-analysis, (EJC 2017)
• STOPCAP 1 (M1) - aggregate data network meta-analysis, (Annals Onc 2018) 
• STOPCAP 1 (M1) – prostate RT, systematic review and aggregate data meta-analysis, (Eur Urol 2019)
• STOPCAP 1 (M1) – docetaxel, systematic review and individual participant data meta-analysis (Lancet Onc 2023) 

Contact details

mrcctu.stopcapm1@ucl.ac.uk

Who funded the study?

The STOPCAP 1 collaboration is funded by Prostate Cancer UK and the Medical Research Council.